Psychiatrist and principal investigator. Two decades of careful science for the people the usual treatments have failed — from autism genetics to Phase 3 psychedelic trials — built on the conviction that rigor and compassion are the same discipline.
Board-certified psychiatrist PI with 250+ trials across MDD, TRD, GAD, PTSD, bipolar, schizophrenia, eating disorders and pediatric indications. DEA Schedule I researcher registration (five drug codes). Site-PI on Phase 3 programs from MindMed, Compass, Cybin, Transcend, Reunion and AbbVie.
See the active portfolio →First author on the 2025 JAMA MM120 trial; co-author on the 2023 JAMA psilocybin trial and the Ogden syndrome discovery. Open to co-authorship, safety-monitoring roles and pragmatic study design.
Read the publications →Board certified since 2010, medical director of an eating-disorder center for nearly a decade, principal investigator on more than 250 trials. Everything here is listed so it can be checked.
Read the CV →Schedule I is the most restricted tier of the U.S. Controlled Substances Act — drugs the DEA classes as having no accepted medical use. A physician cannot simply prescribe or order them; a separate DEA researcher registration is required for each compound, tied to specific protocols, with vault-grade storage, DEA inspection and reconciled accountability for every milligram. Reid holds an active DEA Researcher (Schedule I) registration at Inner Space Research covering five drug codes — the compounds below.
The first adequately powered randomized trial of LSD for an anxiety disorder; a single dose, no adjunctive psychotherapy, durable dose-dependent effect.
Publications →Co-author on the multicenter Usona trial that set the evidentiary bar for psilocybin in major depression.
Publications →Phase 3 psychedelic and novel-mechanism programs: MindMed, Compass, Cybin, Transcend, Reunion, AbbVie, Neurocrine, Janssen.
Now at ISR →Built one of the country's largest ketamine-assisted psychotherapy programs at Cedar Psychiatry, Novamind and Numinus; published outcomes, safety and cost-effectiveness.
Talks →Plus first case series of group ketamine-assisted psychotherapy in residential eating-disorder treatment, and the SPANYA safety committee at UCSF.
Trials →Genome-wide CNV study of ADHD, and VAAST identification of the NAA10 variant behind a lethal X-linked syndrome in Utah families.
Genetics papers →Co-founded Cedar Psychiatry and Cedar Clinical Research; grew into Novamind and Numinus, where he served as CMO and CCO.
Experience →Ninety talks, panels, podcasts and press features, from Smithsonian and Forbes to the Psychiatric Times cover.
Talks →Every format is built from the same data as the rest of the site, so it is never out of date. Copy as text or Markdown, or print to PDF.